Pharmacyclics

Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. 
IMBRUVICA (ibrutinib) is a prescription medicine used to treat people with marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment.

TypeSubsidiary
Parent CompanyAbbVie
HQSunnyvale, US
Founded1991
Websitepharmacyclics.com
Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Pharmacyclics

Erik von Borcke

Erik von Borcke

President
Stefan Geldmeyer

Stefan Geldmeyer

Head of Finance and Infrastructure
Guowei Fang

Guowei Fang

Head of Discovery
Ann Tomlin

Ann Tomlin

Head of Human Resources
Thorsten Graef

Thorsten Graef

Head of Clinical Development
Nancy Burton

Nancy Burton

Head of Ethics and Compliance
Show more

Pharmacyclics Office Locations

Pharmacyclics has an office in Sunnyvale
Sunnyvale, US (HQ)
999 E Arques Ave
Show all (1)

Pharmacyclics Financials and Metrics

Summary Metrics

Founding Date

1991

Investors

Pharmacyclics is a subsidiary of AbbVie

Pharmacyclics Revenue

Pharmacyclics's revenue was reported to be $729.73 m in FY, 2014 which is a 180.5% increase from the previous period.
Annual
USDFY, 2012FY, 2013FY, 2014

Revenue

160.7m260.2m729.7m

Revenue growth, %

180%

Cost of goods sold

3.5m40.4m

Gross profit

256.7m689.3m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Revenue

37.0k77.9m1.9m102.7m2.8m54.7m79.1m119.4m113.0m207.1m205.8m

Cost of goods sold

6.1m9.3m11.6m16.7m

Gross profit

113.3m103.7m195.5m189.1m

Gross profit Margin, %

95%92%94%92%
Annual
USDFY, 2012FY, 2013FY, 2014

Cash

307.4m624.0m845.0m

Accounts Receivable

26.7m11.0m64.3m

Prepaid Expenses

2.7m9.3m20.6m

Inventories

12.6m34.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Cash

86.9m230.2m213.5m276.2m502.5m494.2m548.4m678.6m666.3m724.5m874.7m

Accounts Receivable

37.0k1.2m12.9m8.8m17.2m37.4m53.8m27.0m45.3m53.3m77.0m

Prepaid Expenses

2.6m3.4m2.6m2.6m4.3m10.8m10.5m11.4m12.2m15.2m40.0m

Inventories

28.7m38.3m41.4m49.0m
Annual
USDFY, 2012FY, 2013FY, 2014

Net Income

117.5m67.0m86.1m

Depreciation and Amortization

595.0k2.2m4.4m

Inventories

(12.4m)(21.0m)

Accounts Payable

1.6m(37.0k)3.3m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(14.5m)41.7m(12.8m)75.6m(51.9m)(39.6m)2.8m18.3m(18.8m)22.6m4.1m

Depreciation and Amortization

98.0k213.0k260.0k392.0k878.0k1.5m911.0k2.0m3.2m1.4m

Inventories

(15.8m)(25.0m)(28.0m)(14.5m)

Accounts Payable

1.9m1.8m610.0k9.9m(638.0k)833.0k(2.8m)2.2m(2.0m)(4.4m)
Show all financial metrics

Pharmacyclics Online and Social Media Presence

Embed Graph

Pharmacyclics News and Updates

CEI's Center for Class Action Fairness Appeals Unfair Disclosure-Only Settlement in Pharmacyclics-AbbVie Merger

The Competitive Enterprise Institute’s Center for Class Action Fairness filed the opening brief in an appeal of a “disclosure-only settlement” stemming from the 2015 merger between Pharmacyclics and AbbVie. As in the vast majority of “strike suits” filed in the wake of nearly every merger of large p…

A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash

Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when it introduced a new version of the pill. The new price tag faced criticism from cancer doctors who were concerned about how this would impact how they dosed patients with the drug.  Last week, Pharmacyclics re…

Pharmacyclics Frequently Asked Questions

  • When was Pharmacyclics founded?

    Pharmacyclics was founded in 1991.

  • Who are Pharmacyclics key executives?

    Pharmacyclics's key executives are Erik von Borcke, Stefan Geldmeyer and Guowei Fang.

  • What is Pharmacyclics revenue?

    Latest Pharmacyclics annual revenue is $729.7 m.

  • Who are Pharmacyclics competitors?

    Competitors of Pharmacyclics include Northwest Biotherapeutics, Merrimack Pharmaceuticals and CytomX Therapeutics.

  • Where is Pharmacyclics headquarters?

    Pharmacyclics headquarters is located at 999 E Arques Ave, Sunnyvale.

  • Where are Pharmacyclics offices?

    Pharmacyclics has an office in Sunnyvale.

  • How many offices does Pharmacyclics have?

    Pharmacyclics has 1 office.